RxDoctor Payments Data

Caroline Pratz

Acute Care · Philadelphia, PANPI 1033346200

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $51,968 of the $76,931 with a category attached, or 67.6%. 7 manufacturers reported payments, led by Pfizer at 58.1% of the total. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,931in general payments, 2019–2025

Across 145 payments — averaging $530.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$45K
  • Merck$17K
  • Astellas Pharma US Inc$8K
  • Seagen Inc.$7K
  • Janssen Scientific Affairs, LLC$390
  • Hologic Sales And Service, LLC$14
  • plus $3 from 1 others
$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1K

What the payments were for

  • Consulting fees$3,0344%
  • Speaking & faculty fees$51,96868%
  • Travel & lodging$18,22124%
  • Food & beverage$3,7085%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,931 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.

See all acute care providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,596
Medicare patients
73
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib23$387,234
NeulastaPegfilgrastim19$150,808
CreonLipase/Protease/Amylase48$115,444
Imatinib Mesylate17$105,251
Somatuline DepotLanreotide Acetate11$105,077
EliquisApixaban31$26,042
OxycontinOxycodone Hcl12$16,466
Aprepitant40$7,226
Oxycodone Hcl79$1,424
LoperamideLoperamide Hcl36$766
Dexamethasone29$565
Prochlorperazine Maleate30$560
Ondansetron Hcl37$407
Sodium Chloride0.9 % Sodium Chloride26$356
Omeprazole35$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44,685$26,04231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.

Other acute care in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →